Metropolitan Life Insurance CO Revance Therapeutics, Inc. Transaction History
Metropolitan Life Insurance CO
- $2.27 Billion
- Q1 2024
A detailed history of Metropolitan Life Insurance CO transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Metropolitan Life Insurance CO holds 3,633 shares of RVNC stock, worth $9,336. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,633
Previous 4,832
24.81%
Holding current value
$9,336
Previous $42,000
59.52%
% of portfolio
0.0%
Previous 0.0%
Shares
53 transactions
Others Institutions Holding RVNC
# of Institutions
214Shares Held
83.4MCall Options Held
656KPut Options Held
424K-
Capital World Investors Los Angeles, CA13.9MShares$35.8 Million0.01% of portfolio
-
Black Rock Inc. New York, NY7.31MShares$18.8 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA6.28MShares$16.1 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.4MShares$13.9 Million0.0% of portfolio
-
Palo Alto Investors LP Palo Alto, CA5.25MShares$13.5 Million3.02% of portfolio
About Revance Therapeutics, Inc.
- Ticker RVNC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 82,305,696
- Market Cap $212M
- Description
- Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...